The phase III CheckMate -649 demonstrated that first-line treatment with Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in the overall survival and progression-free survival of patients with unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma compared to treatment with chemotherapy alone.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
